WithdrawnNCT02663648

Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders

Studying Chronic myeloid leukemia

Last synced from ClinicalTrials.gov May 18, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Shandong University
Principal Investigator: Jun Peng
Qilu Hospital of Shandong University
Eligibility: 18-80 years · All sexes
Timeline: 2016 – 2020

Study locations (1)

Qilu Hospital, Shandong University, Jinan, Shandong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02663648 on ClinicalTrials.gov

Other trials for Chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis Pharmaceuticals
RECRUITINGNCT07375355
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Novartis Pharmaceuticals
ENROLLING BY INVITATIONNCT07383298
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
Qian Jiang
RECRUITINGPHASE2NCT06817720
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
RECRUITINGNCT07061145
A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
Azienda USL Reggio Emilia - IRCCS
RECRUITINGPHASE2NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Gruppo Italiano Malattie EMatologiche dell'Adulto
RECRUITINGPHASE2NCT06514534
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Novartis Pharmaceuticals
RECRUITINGPHASE1NCT06787144
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Enliven Therapeutics

See all trials for Chronic myeloid leukemia →

← Back to all trials